

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

NOVO NORDISK A/S,
Patent Owner

Case IPR2023-00722
Patent 8,536,122

**PATENT OWNER'S PRELIMINARY RESPONSE
UNDER 37 C.F.R. § 42.107**

LIST OF EXHIBITS

| Exhibit | Description |
|----------------|--|
| EX2001 | Excerpt of Defendants' Initial Invalidation Contentions, <i>In re: Ozempic (Semaglutide) Patent Litigation</i> , No. 1:22-cv-01040-CFC, (D. Del. Oct. 20, 2022) |
| EX2002 | J. Lau, P. Bloch, et al., "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide," <i>Med. Chem.</i> , 58:7370-7380 (2015) |
| EX2003 | U.S. Patent No. 10,335,462 |
| EX2004 | B. Furman, N. Pyne, P. Flatt & F. O'Harte, "Targeting B-cell cyclic adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus," <i>J. Pharmacy and Pharmacology</i> , 56:1477-1492 (2004) |
| EX2005 | WO98/32466 |
| EX2006 | U.S. Patent No. 6,528,486 |
| EX2007 | WO00/69911 |
| EX2008 | Declaration of Sayem Osman |

TABLE OF CONTENTS

I. Introduction..... 1

II. Challenged Claims Are Directed To A Novel, Non-Obvious Invention5

III. Petitioner’s References Identify Thousands of Compounds and Potential Modifications9

 A. Knudsen 2004 (EX1010).....9

 B. Knudsen 2001 (EX1011).....9

 C. Knudsen Patent (EX1012).....12

 D. Dong (EX1013)14

 E. Bridon (EX1014).....15

IV. Claim Construction.....16

V. §314(a) Discretionary Denial: Ground 3 Fails to Identify “With Particularity” Each Reference and Combination on Which the Challenge is Based, and Its Extraordinary, Prejudicial Impropriety Requires Denial..... 16

VI. Grounds 1-2: Petitioner’s Lead Compound Analysis Is Legally Deficient .20

 A. Petitioner’s Lead Compound Analysis Fails.....20

 B. Even if Liraglutide Were Selected as a Lead Compound, Petitioner Fails to Establish “Motivation To Combine”25

 1. Petitioner Ignores The Numerous Types and Locations of Potential Modifications to Liraglutide Other than Those Found in Semaglutide.....26

 2. Even Focusing on the Types of Modifications Needed to Arrive at Semaglutide, Petitioner Ignores The Numerous Options for Implementing Those Modifications29

 C. Petitioner Fails To Establish A Reasonable Expectation Of Success In Creating Semaglutide46

 1. Petitioner Fails to Show REOS For Individual Modifications .47

 2. Petitioner Fails to Show REOS For Its Argued Combination of Modifications51

VII. Ground 3: Petitioner’s Obvious-To-Try Analysis Fails52

VIII. Institution Should Be Denied Under 35 U.S.C. §325(d).....57

 A. Advanced Bionics Part One59

 B. Advanced Bionics Part Two.....66

IX. Conclusion69

TABLE OF AUTHORITIES

| | Page(s) |
|--|----------------|
| Cases | |
| <i>Adaptics Ltd. v. Perfect Co.</i> , IPR2018-01596, Pap.20 (Mar. 6, 2019) (informative)..... | <i>passim</i> |
| <i>Adidas AG v. Nike, Inc.</i> , 963 F.3d 1355 (Fed. Cir. 2020) | 36, 40 |
| <i>ADT LLC v. Vivint, Inc.</i> , IPR2022-00634, Pap.7 (Oct. 4, 2022) | 17, 19 |
| <i>Advanced Bionics, LLC v. MED-EL Elektromedizinische Gerate GmbH</i> , IPR2019-01469, Pap.6 (Feb. 13, 2020) (precedential)..... | <i>passim</i> |
| <i>Alarm.com, Inc. v. Vivint, Inc.</i> , IPR2022-00728, Pap.6 (Nov. 1, 2022) | 62 |
| <i>Apple Inc. v. Universal Secure Registry, LLC</i> , IPR2018-00808, Pap.9 (Oct. 9, 2018) | 53 |
| <i>In re Applied Materials, Inc.</i> , 692 F.3d 1289 (Fed. Cir. 2012) | 50 |
| <i>Autel Intelligent Tech. Corp. v. Orange Elec. Co.</i> , IPR2021-01545, Pap.8 (Apr. 8, 2022)..... | 62 |
| <i>Becton, Dickinson and Co. v. B. Braun Melsungen AG</i> , IPR2017-01586, Pap.8 (Dec. 15, 2017) (precedential) | 58, 59, 61 |
| <i>Bioeq IP AG v. Genentech, Inc.</i> , IPR2016-01608, Pap.11 (Feb. 22, 2017) | 32, 34, 35, 45 |
| <i>In re Boesch</i> , 617 F.2d 272 (C.C.P.A. 1980)..... | 57 |
| <i>CSL Behring LLC v. Bioverative Therapeutics Inc.</i> , IPR2018-01313, Pap.10 (Jan. 9, 2019)..... | 34, 42, 45 |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.